NASDAQ:VSAR Versartis Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Versartis Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.19 0.00 (0.00 %) (As of 10/15/2018) Add Compare Share Today's Range$1.18Now: $1.19▼$1.3050-Day Range$1.19MA: $1.19▼$1.1952-Week Range$1.14Now: $1.19▼$2.76Volume349,963 shsAverage Volume479,436 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Versartis. Previous Next 2.6 Community Rank Outperform VotesVersartis has received 314 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVersartis has received 288 “underperform” votes. (Add your “underperform” vote.)Community SentimentVersartis has received 52.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote “Outperform” if you believe VSAR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVersartis does not currently pay a dividend.Dividend GrowthVersartis does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Versartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.90% of the stock of Versartis is held by insiders.Percentage Held by Institutions38.52% of the stock of Versartis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.72 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VSAR Previous Symbol CUSIPN/A CIK1513818 Webwww.versartis.com Phone650-963-8580Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable Receive VSAR News and Ratings via Email Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter. Versartis (NASDAQ:VSAR) Frequently Asked Questions How were Versartis' earnings last quarter? Versartis Inc (NASDAQ:VSAR) posted its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.69. View Versartis' earnings history. Who are some of Versartis' key competitors? Some companies that are related to Versartis include Acusphere (ACUS), Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aoxing Pharmaceutical (AOXG), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), China Health Industries (CHHE) and Diadexus (DDXSQ). View all competitors. What other stocks do shareholders of Versartis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Versartis investors own include Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP), Bausch Health Companies (BHC), Genocea Biosciences (GNCA), Novavax (NVAX), Cara Therapeutics (CARA), Flexion Therapeutics (FLXN), Protalix Biotherapeutics (PLX), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP). Who are Versartis' key executives? Versartis' management team includes the following people: Mr. Jay P. Shepard, Pres, CEO & Director (Age 60)Ms. Tracy M. Woody, Chief Commercial Officer (Age 48)Dr. Jeffrey L. Cleland, Co-Founder (Age 53)Dr. Joshua Silverman Ph.D., Co-FounderMr. Kevin Haas, VP of Fin. (Age 53) What is Versartis' stock symbol? Versartis trades on the NASDAQ under the ticker symbol "VSAR." What is Versartis' stock price today? One share of VSAR stock can currently be purchased for approximately $1.19. What is Versartis' official website? The official website for Versartis is www.versartis.com. How can I contact Versartis? Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected] This page was last updated on 9/28/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
